New combo therapy aims to halt ovarian Cancer's return
NCT ID NCT04387227
Summary
This study is testing if a two-drug combination can stop ovarian, fallopian tube, or primary peritoneal cancer from getting worse after it has come back. The treatment pairs an immunotherapy drug (pembrolizumab) that helps the immune system fight cancer with a chemotherapy drug (carboplatin) that kills cancer cells. The goal is to see if this combination can prevent the cancer from progressing in patients whose blood tests show signs of recurrence but who don't yet have visible tumors on scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.